A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer

Abstract

In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites. (ClinicalTrials.gov number, NCT00004205.)